Online inquiry

IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ440MR)

This product GTTS-WQ440MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets AMHR2 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001164690.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 269
UniProt ID Q16671
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ440MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12333MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ2324MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ1795MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ10302MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ10640MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ1700MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ13715MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ11893MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-1202
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW